Last reviewed · How we verify

Metronidazole (ST14)

National Taiwan University Hospital · FDA-approved active Small molecule

Metronidazole (ST14) is a Nitroimidazole antibiotic Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Anaerobic bacterial infections (intra-abdominal, gynecological, respiratory), Trichomoniasis, Giardiasis. Also known as: Flagyl.

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after reduction of its nitro group.

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced in anaerobic environments. Used for Anaerobic bacterial infections, Trichomoniasis, Amebiasis.

At a glance

Generic nameMetronidazole (ST14)
Also known asFlagyl
SponsorNational Taiwan University Hospital
Drug classNitroimidazole antibiotic
TargetBacterial/parasitic DNA
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

The drug is activated by anaerobic bacteria and parasites through reduction of its 5-nitro group, generating cytotoxic free radicals that damage DNA and prevent replication. This mechanism makes it effective against obligate anaerobes and certain protozoan parasites. It has no activity against aerobic organisms due to their inability to activate the drug.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metronidazole (ST14)

What is Metronidazole (ST14)?

Metronidazole (ST14) is a Nitroimidazole antibiotic drug developed by National Taiwan University Hospital, indicated for Anaerobic bacterial infections (intra-abdominal, gynecological, respiratory), Trichomoniasis, Giardiasis.

How does Metronidazole (ST14) work?

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after reduction of its nitro group.

What is Metronidazole (ST14) used for?

Metronidazole (ST14) is indicated for Anaerobic bacterial infections (intra-abdominal, gynecological, respiratory), Trichomoniasis, Giardiasis, Amebiasis, Clostridioides difficile infection.

Who makes Metronidazole (ST14)?

Metronidazole (ST14) is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

Is Metronidazole (ST14) also known as anything else?

Metronidazole (ST14) is also known as Flagyl.

What drug class is Metronidazole (ST14) in?

Metronidazole (ST14) belongs to the Nitroimidazole antibiotic class. See all Nitroimidazole antibiotic drugs at /class/nitroimidazole-antibiotic.

What development phase is Metronidazole (ST14) in?

Metronidazole (ST14) is FDA-approved (marketed).

What are the side effects of Metronidazole (ST14)?

Common side effects of Metronidazole (ST14) include Metallic taste, Nausea, Headache, Peripheral neuropathy (with prolonged use), Disulfiram-like reaction with alcohol, Diarrhea.

What does Metronidazole (ST14) target?

Metronidazole (ST14) targets Bacterial/parasitic DNA and is a Nitroimidazole antibiotic.

Related